{"doi":"10.1016/j.lanmic.2024.100984","title":"Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trial","abstract":"BACKGROUND: Although existing COVID-19 vaccines are known to be highly effective against severe disease and death, data are needed to assess their ability to reduce SARS-CoV-2 infection. We aimed to estimate the efficacy of the NVX-CoV2373 protein subunit vaccine against SARS-CoV-2 infection, regardless of symptoms, among adolescents. METHODS: We performed an ancillary observational study (SNIFF) to the phase 3, observer-blinded, randomised, placebo-controlled PREVENT-19 trial that assessed vaccine efficacy against symptomatic COVID-19 in the USA. Participants in the PREVENT-19 trial included healthy adolescents aged 12-17 years and with no history of laboratory-confirmed SARS-CoV-2 infection. They were randomly assigned (2:1) to receive either the NVX-CoV2373 (Novavax, Gaithersburg, MD, USA) vaccine (immediate NVX-CoV2373 group) or placebo (delayed NVX-CoV2373 group) on days 0 and 21 (initial series). After 2 months, in a crossover series, participants received two doses, 21 days apart, of the intervention that they did not receive in their initial series. Participants at 47 of the PREVENT-19 sites were invited to participate in the SNIFF study and self-collect nasal swabs at home twice weekly for SARS-CoV-2 testing to assess vaccine efficacy against SARS-CoV-2 infection. This primary outcome was defined as the first identification of SARS-CoV-2 detected by RT-PCR, regardless of symptoms, with onset within 4 weeks after the second dose of the initial vaccination series until the second dose of the crossover series. Secondary outcomes were vaccine efficacy against asymptomatic and minimally symptomatic SARS-CoV-2 infection, durability of vaccine efficacy against SARS-CoV-2 infection, and durability of vaccine efficacy against asymptomatic and minimally symptomatic infections. Outcomes were analysed in the modified intention-to-treat population, which included all participants without previous SARS-CoV-2 infection and was restricted to participants enrolled within 4 weeks of the second dose of the primary (primary analysis population) or crossover (post-crossover analysis population) series. This study is registered with ClinicalTrials.gov (NCT04611802). FINDINGS: Between June 1 and Dec 17, 2021, 1196 (53·2%) of the 2247 adolescent participants recruited in the PREVENT-19 trial enrolled in the SNIFF study. The primary analysis population included 471 participants in the immediate NVX-CoV2373 group and 220 in the delayed NVX-CoV2373 group. Incidence of SARS-CoV-2 infection was 14·9 cases per 100 person-years (95% CI 7·9-25·5) in the immediate group and 54·2 cases per 100 person-years (33·6-82·9) in the delayed group; vaccine efficacy was 73·5% (95% CI 47·1-86·7; p=0·0002). Incidence of minimally symptomatic or asymptomatic SARS-CoV-2 infection was 10·3 cases per 100 person-years (95% CI 4·7-19·6) in the immediate group and 36·1 cases per 100 person-years (19·8-60·7) in the delayed group; vaccine efficacy was 72·8% (95% CI 37·1-88·2; p=0·0023). After the second crossover dose, incidence of SARS-CoV-2 was 14·6 cases per 100 person-years (95% CI 8·6-23·0) in the immediate group (receiving placebo at crossover) and 9·1 cases per 100 person-years (3·0-21·3) in the delayed group, with a durability ratio of 160·3 (95% CI 59·5-431·6; p=0·35). Almost all infections after crossover were minimally symptomatic or asymptomatic, with a durability ratio of 151·4 (55·9-410·4; p=0·41). INTERPRETATION: Among adolescents participating in the PREVENT-19 trial during the delta (B.1.617.2) variant wave of the COVID-19 pandemic, the NVX-CoV2373 vaccine was highly efficacious against SARS-CoV-2 infection regardless of symptoms, indicating its potential to reduce the reservoir of infections that contribute to community transmission. FUNDING: US Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, National Institute of Allergy and Infectious Diseases, and ","journal":"The Lancet Microbe","year":2025,"id":530998,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":2,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9646,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT04611802"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":32390,"name":"Elizabeth R. Brown","orcid":"0000-0003-4286-2111","position":1,"is_corresponding":false},{"id":667497,"name":"Monica A. McArthur","orcid":"0000-0003-2605-3752","position":2,"is_corresponding":false},{"id":227082,"name":"Stephanie J. Schrag","orcid":"0000-0002-8113-2544","position":3,"is_corresponding":false},{"id":314165,"name":"Melissa Arvay","orcid":"0000-0003-3502-4259","position":4,"is_corresponding":false},{"id":382435,"name":"Mike Humphrys","orcid":null,"position":5,"is_corresponding":false},{"id":19828,"name":"Jacques Ravel","orcid":"0000-0002-0851-2233","position":6,"is_corresponding":false},{"id":804962,"name":"Jeffrey Adelglass","orcid":null,"position":7,"is_corresponding":false},{"id":615313,"name":"Brandon Essink","orcid":"0000-0002-7309-228X","position":8,"is_corresponding":false},{"id":804967,"name":"David B. Musante","orcid":null,"position":9,"is_corresponding":false},{"id":846025,"name":"Rebecca Maguire","orcid":"0000-0002-0368-4626","position":10,"is_corresponding":false},{"id":1411304,"name":"Richard L. Gorman","orcid":null,"position":11,"is_corresponding":false},{"id":1411305,"name":"Elizabeth Formentini","orcid":null,"position":12,"is_corresponding":false},{"id":438186,"name":"Robín Masón","orcid":"0000-0003-3143-6811","position":13,"is_corresponding":false},{"id":288619,"name":"Merlin L. Robb","orcid":"0000-0003-3949-9649","position":14,"is_corresponding":false},{"id":38212,"name":"Kathleen M. Neuzil","orcid":"0000-0001-9480-2714","position":15,"is_corresponding":false},{"id":528542,"name":"Rekha R. Rapaka","orcid":"0000-0002-4770-4422","position":16,"is_corresponding":false},{"id":91436,"name":"P. A. Wolff","orcid":null,"position":17,"is_corresponding":false},{"id":242121,"name":"Karen L. Kotloff","orcid":"0000-0003-1808-6431","position":18,"is_corresponding":false},{"id":98393,"name":"Brandon Essink","orcid":null,"position":28,"is_corresponding":false},{"id":1411306,"name":"David Musante","orcid":null,"position":29,"is_corresponding":false},{"id":1411307,"name":"Richard Gorman","orcid":null,"position":31,"is_corresponding":false},{"id":1411308,"name":"Robin Mason","orcid":null,"position":33,"is_corresponding":false},{"id":1411309,"name":"Rekha Repaka","orcid":null,"position":36,"is_corresponding":false},{"id":1411310,"name":"Peter Wolff","orcid":null,"position":37,"is_corresponding":false},{"id":1411311,"name":"Ronald Ackerman","orcid":null,"position":40,"is_corresponding":false},{"id":1411312,"name":"Elizabeth Barranco-Santana","orcid":null,"position":41,"is_corresponding":false},{"id":1083939,"name":"Laurence Chu","orcid":"0000-0002-8950-6117","position":42,"is_corresponding":false},{"id":104972,"name":"Stuart H. Cohen","orcid":null,"position":43,"is_corresponding":false},{"id":1411313,"name":"Wendy Daly","orcid":null,"position":44,"is_corresponding":false},{"id":1411314,"name":"Kenneth Etokhana","orcid":null,"position":45,"is_corresponding":false},{"id":1411315,"name":"Cynthia Gay","orcid":null,"position":46,"is_corresponding":false},{"id":1084388,"name":"Greg Hachigian","orcid":null,"position":47,"is_corresponding":false},{"id":702802,"name":"Robert Jeanfreau","orcid":null,"position":48,"is_corresponding":false},{"id":901451,"name":"Vicki E. Miller","orcid":null,"position":49,"is_corresponding":false},{"id":1084392,"name":"William Seger","orcid":null,"position":50,"is_corresponding":false},{"id":1411316,"name":"Joanna Sexter","orcid":null,"position":51,"is_corresponding":false},{"id":1411317,"name":"Marian E. Shaw","orcid":null,"position":52,"is_corresponding":false},{"id":1411318,"name":"Kenneth Steil","orcid":null,"position":53,"is_corresponding":false},{"id":30684,"name":"Christine B. Turley","orcid":"0000-0001-8079-9382","position":54,"is_corresponding":false},{"id":1411319,"name":"Michael Waters","orcid":null,"position":55,"is_corresponding":false},{"id":415858,"name":"Meagan E. Deming","orcid":"0000-0003-2574-0542","position":0,"is_corresponding":true}],"reference_count":35,"raw_metadata":null,"created_at":"2026-07-19T02:51:10.077559Z","pmid":"39884302","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}